Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents

J Am Acad Dermatol. 2014 Jun;70(6):e136-7. doi: 10.1016/j.jaad.2013.12.011.

Authors

Aaron R Mangold¹, Christine M Cole², David J DiCaudo¹, Mark R Pittelkow¹, Aleksandar Sekulic³

Affiliations

¹ Department of Dermatology, Mayo Clinic, Phoenix, Arizona.
² Department of Dermatology, Mayo Clinic, Phoenix, Arizona; Center for Dermatology Care, Thousand Oaks, California.
³ Department of Dermatology, Mayo Clinic, Phoenix, Arizona. Electronic address: [email protected].

PMID: 24831336
DOI: 10.1016/j.jaad.2013.12.011

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Administration, Topical
Amitriptyline / therapeutic use
Drug Therapy, Combination
Epidermolysis Bullosa / diagnosis
Epidermolysis Bullosa / drug therapy*
Epidermolysis Bullosa / pathology*
Epidermolysis Bullosa Dystrophica
Female
Follow-Up Studies
Gels
Humans
Ketamine / therapeutic use
Lower Extremity
Middle Aged
Risk Assessment
Sertraline / administration & dosage*
Severity of Illness Index
Treatment Outcome

Substances

Gels
Amitriptyline
Ketamine
Sertraline

Supplementary concepts

Epidermolysis Bullosa Pruriginosa